The content on this site is intended for healthcare professionals only
Dr Ying Huang speaks to ecancer about the first-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
He explains that LB2501 is designed to generate CAR-T cells directly within the patient, eliminating the need for ex vivo manufacturing and lymphodepleting chemotherapy. The treatment is administered as a single intravenous infusion and represents a novel off-the-shelf approach to CAR-T therapy.
Dr Huang report a favourable safety profile, with no dose-limiting toxicities, serious adverse events, or neurotoxicity observed. At the higher dose level, the objective response rate was 100% and the complete response rate was 83.3%, with all responses ongoing at the time of analysis.
These early findings demonstrate the feasibility of in vivo CAR-T generation and support further development of LB2501 as a potentially more accessible cellular immunotherapy for B-cell malignancies.
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab
Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone
